The average pharma company clinical trial diversity policy contains less than half of the commitments recommended by the US Food and Drug Administration, other regulators, and industry trade groups to improve the composition of their studies, a new BMJ study found.
Gaps Found In Most Pharma Trial Diversity Policies
A study suggests industry groups like PhRMA could use more of their influence to hold members accountable on trial diversity policies.
